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1 pathogenic eosinophils in the lungs of allergic mice that are also present in the tissues of patients with allergic diseases.
We have shown the significance of IL-18 in eosinophil differentiation, maturation, activation, and transformation from naive to pathogenic eosinophils. Additionally, these data authenticate that both the CD101-expressing and CD274-expressing eosinophil subsets are not IL-5 dependent, as reported earlier. 4 These investigations also indicate that IL-5-independent hidden eosinophils identified in an earlier report are immature residential eosinophils in normal lungs that mature after HDM challenge in asthmatic mice. 4 The mature and activated pathogenic eosinophils that accumulate in the tissues of patients with allergic diseases are CD101 1 CD274
1
. These double-positive pathogenic eosinophils are observed in the tissue of both mice and human subjects under allergic conditions. Moreover, this study also shows some discrepancy in expression levels of CD101 in the blood of healthy human subjects and mice, which might be due to the well-controlled conditions of age, environment, and food provided to the mice. In addition, analyzed healthy human subjects have some limitations, such as the analyzed age group (14-48 years), different food habits, and environmental conditions. The range of CD101 expression levels in blood eosinophils of healthy subjects clearly denote this possibility and might be the reason for this observed discrepancy. This CD101 expression discrepancy also explains the wisdom of earlier reported CD101-expressing eosinophils in allergic mice but not in allergic human subjects compared with the respective healthy subjects. 4 In conclusion, for the first time, the presented data authenticate a critical role for IL-18 in the development and transformation of distinct pathogenic eosinophils in patients with allergic diseases.
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To the Editor:
Recent studies have demonstrated that the number of group 3 innate lymphoid cells (ILC3s) is increased in peripheral blood, lesional skin, and nonlesional skin of patients with psoriasis.
1,E1,E2
However, definitive evidence is as yet entirely missing that these innate immunocytes, which produce IL-22 and IL-17, but not TNF-a or IFN-g, and lack cytotoxic effectors, E2 are functionally involved in the induction of psoriatic lesions in human skin. Hence, the present study aimed to determine whether human ILC3s (ie, CD32 RORgt1 NKp441 cells) E1 suffice to induce psoriatic lesions in healthy human skin in vivo.
This was tested in a well-established humanized mouse model of psoriasis, in which skin lesions that are indistinguishable from the human disease are induced in healthy human skin xenotransplants by intradermal injection of autologous, preactivated PBMCs. 2,3,E3-E5 Normal donor skin from healthy female volunteers aged 46 6 10 years was transplanted onto severe combined immunodeficient/beige mice and 20 mL of venous blood was obtained from the same donors as described. E3 The study was approved by the Institutional Ethics Committee of Rambam Medical Center, Haifa, Israel. First, ILC3s were purified from cultured PBMCs and characterized for subsequent injection into the xenotransplants. To (see Fig E2, A, in this article's Online Repository at www. jacionline.org).
5,E8
These IL21AhR-activated cell cultures were magnetically separated into purified ILC3s and T H 17/Tc17 cells (Fig E2, B) . Negative control cells were generated from IL2-activated PBMCs with/without AhR agonist (see Fig E2, C, and Fig E3, A, in this article's Online Repository at www.jacionline.org). Flow cytometric analysis documented the absence of gd T cells and natural killer (NK) cells in the ILC3 preparation, while 5% gd T cells and NK cells were present in the T H 17/Tc17 cell cultures (Fig E2, D) . 6 The purified ILC3s were associated with the expected intracellular cytokine expression pattern 5,7,E9 : 78% of ILC3s showed Quantitative data of epidermal thickness of (C) ki67, (E) HLA-DR, S100A, HBD2, (I) CD4, CD8, and pDCs (M) in the control and ILC3s versus the remaining tested groups. H&E, Hematoxylin and eosin; pDC, plasmacytoid dendritic cells.
IL-22 expression, and 10% 6 3% of these cells were doublepositive for both IL-17 and IL-22 (Fig E3, B) . For comparison, in line with the literature, E10 47% of T H 17/Tc17 cells expressed IL-17, with 19% being double-positive for both IL-17 and IL-22 (Fig E3, B) . This intracellular expression pattern of IL-22 and in ILC3s is known to be associated with ILC3 activation, and the predominance of intracellular IL-22 over IL-17 seen here is perfectly in line with the ILC3 literature.
8,E11 A similar expression pattern was observed in cells of normal healthy donors and patients with psoriasis ( Fig E3, C) .
Next, we tested whether the purified ILC3s suffice to induce psoriatic lesions in normal human skin xenografts derived from 11 healthy female volunteers transplanted onto 68 female severe combined immunodeficient/beige mice, as previously described.
2,E3-E5
These xenotransplants were injected intradermally with PBMCs E4 that had been subjected to several different culture conditions. The mice were divided as follows: 8 mice received autologous IL2-activated PBMCs. As expected, E3,E4 all of these positive control mice demonstrated the characteristic macroscopic (Fig 1, A) and histological features of psoriasis (Fig 1, B and C) including epidermal thickening and parakeratosis, munro microabscesses, hypogranulosis, elongation of rete ridges, and dilated tortuous blood vessels in the dermal papilla (Fig 1, B) . As an additional positive control group, 18 mice were injected with purified T H 17/Tc17 cells.
As expected, 15 of 18 (83%) of these mice developed psoriatic lesions following graft injection (Fig 1, B) . In contrast, 2 negative control groups injected with CD3 (2) NKp44(2) cells obtained from PBMCs cultured with IL-2 without or with AhR agonist failed to develop any psoriasis features (Fig 1, A-C) . These findings indicate that it is it highly unlikely that a small number of other, AhR agonist-stimulated cells had contaminated the purified ILC3 cell preparation and was responsible for inducing psoriatic lesions.
Most importantly, 17 of 22 (77%) mice, which were injected only with purified autogolous ILC3s, developed the characteristic macroscopic and histological features of psoriatic skin lesions (Fig 1, A-C) .
Quantitative (immuno-)histomorphometry revealed that, compared with the negative control groups, ILC3-injected human skin xenotransplants had a significantly thicker epidermis (P < .04) and significantly higher epidermal expression levels of multiple key psoriatic read-out parameters (P < .03) (Fig 1,  D-M ; for details and quantitative data, see Fig 1, I and M), just as in the positive control xenotransplants injected with either IL2-activated PBMCs or T H 17 cells (P < .03) (Fig 1, D-M ; for quantitative data, see Fig 1, I and M).
FIG 2. A-D,
Cytokine expression comparing control with tested groups. E, Quantitative comparison. CD3 immunostaining of ILC3 xenotransplants (F) versus grafts treated with OKT3 (G). Macroscopic (H and I) and microscopic (J and K) appearance of ILC3 xenotransplants (Fig 2, H and J) versus grafts treated with OKT3 (Fig 2, I and K). Quantitative data of CD3 cells number in the 2 groups (L).
Interestingly, even though significantly fewer IL-17 protein1 cells were seen in ILC3-injected xenografts compared with positive control grafts injected with IL2-activated PBMCs or T H 17/Tc17 cells (P < .002), ILC3 injection sufficed to induce psoriatic lesions (Fig 2, A and B) .
As expected, the upregulation of T-cell-related dermal infiltrate markers (ie, CD4, CD8, and plasmacytoid dendritic cells) (P < .005) 9 ( Fig 1, J-M ) was restricted to positive control grafts injected with IL2-activated PBMCs or T H 17 cells. These quantitative immunohistomorphomety data at the protein level were essentially confirmed at the mRNA level by extensive quantitative RT-PCR analyses for the read-out parameters listed above (for details, see text in this article's Online Repository at www.jacionline.org and Fig E3, D) .
To ensure that dermal resident cells or residual CD31 cells within the purified ILC3s were not involved in psoriasis induction, a group of grafted mice was sublethally irradiated before the injection of cultured cells or treated daily with anti-CD31 cell (OKT3) antibodies for 30 days just after the cell injections. This demonstrated that neither irradiation nor injections of anti-CD31 antibodies prevented the induction of the psoriatic lesions in human skin xenotransplants in vivo by autologous ILC3s (Fig 2, F-L) . Furthermore, the psoriasisinducing activity in human skin in vivo appeared to be T-cell-independent and was specific to ILC3, but not to ILC1 or ILC2 cells (Fig E4, A-D) .
To our knowledge, the current study provides the first functional evidence that ILC3 cells are not only numerically increased in human psoriatic skin but can actually drive development of the human psoriatic phenotype and are sufficient to do so, even in the absence of T H 17 cells. This observation, combined with the fact that ILCs promote T-cell activation, E8 Glutathione and arginine levels: Predictors for acetaminophenassociated asthma exacerbation?
To the Editor:
We recently demonstrated that as-needed use of acetaminophen (vs ibuprofen) was not associated with a higher incidence of asthma exacerbations or worse asthma control in young children with mild persistent asthma. 1 However, given prior epidemiological observations of more frequent acetaminophen use and greater asthma impairment in children, 2 it remains unclear whether there are subgroups of children with asthma at increased risk for poorer outcomes with acetaminophen exposure. The purported mechanism linking asthma and acetaminophen is a reduction in the antioxidant glutathione, which conjugates acetaminophen for excretion. While this process is crucial for detoxification, it also irreversibly consumes glutathione stores, resulting in increased and prolonged circulation of highly reactive intermediates (ie, ''oxidant stress'').
Abnormalities in glutathione and arginine metabolic pathways have been described in asthma, albeit in isolation, 3, 4 but each may potentially disrupt the balance of endogenous oxidationreduction (redox) reactions and contribute to oxidant stress. Whereas glutathione is a tripeptide thiol antioxidant, arginine is a conditionally essential amino acid that functions as the obligate substrate for nitric oxide production through the actions of the nitric oxide synthase (NOS) enzymes. The paradigm uniting these mechanisms involves S-nitrosoglutathione, an endogenous airway smooth muscle relaxant that is decreased in the airways of patients with asthma. Low glutathione contributes to dysfunction of NOS enzymes, resulting in decreased coupling of nitric oxide to glutathione to form S-nitrosoglutathione, with increased reactive nitrogen species formation. In addition, low arginine bioavailability results in decreased substrate availability for NOS isoforms, resulting in less S-nitrosothiol formation and increased bronchoconstriction.
Inflammation simultaneously upregulates NOS and the arginine-consuming enzyme arginase, found to be elevated in children with asthma. 4 Arginase metabolizes arginine away from nitric oxide production toward ornithine and downstream byproducts of proline and polyamines, which can contribute to airway
METHODS Patients
Eleven healthy female volunteers aged 46 6 10 years (range, 37-56 years) were included in this study. Normal healthy donor skin was transplanted onto severe combined immunodeficient/beige mice as previously described. E3-E5 Twenty milliliter of venous blood was obtained from the same donors. Blood was also obtained from 5 patients aged 53 years (range, 44-61 years) with psoriasis. The study was approved by the Institutional Ethics Committee of Rambam Medical Center, Haifa, Israel.
Humanized mouse model of psoriasis
Sixty-eight C.B-17/IcrHsd-scid-bg mice were used (Harlan, Jerusalem, Israel). Animal handling was in accordance with the national guidelines and approved by the Technion Animal Care and Use Committee.
Culture of cells with IL2 and AhR agonist
To obtain an enriched RORgt 1 cell culture, PBMCs from 8 normal volunteers were incubated with a high dose of IL-2 (100 U/mL) and AhR agonist E12,E13 200 nM (6-formylindolo carbazole, Enzo) for 14 days.
E7
Magnetic isolation of T H 17-cell and ILC subsets from IL21AhR-activated PBMC cultures
Separation was performed using anti-CD3 antibodies conjugated to ferromagnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and directed through a cell separation column containing a magnetic field (Miltenyi Biotec). For the purification of T H 17 cells, CD31 sorted cells were stained with anti-NKp44-PE conjugated to ferromagnetic microbeads (Miltenyi Biotec) and directed through a cell separation column containing a magnetic field. T H 17 phenotype was confirmed by FACS analysis. Cells were injected (1 3 10 7 ) into the implanted grafts. For the purification of ILC3s, CD32 sorted cells were collected and stained with anti-NKp44-PE conjugated to ferromagnetic microbeads (Miltenyi Biotec) and directed through a cell separation column containing a magnetic field. ILC3s' phenotype was confirmed by FACS analysis, and cells were injected (1 3 10 7 ) into the implanted grafts. For control experiments, PBMCs were incubated for 14 days with IL-2 alone or with AhR agonist 200 nM for 14 days. CD31 cells were depleted with anti-CD3 antibody. CD32 cells were depleted with anti-NKp44 antibody to produce a remaining cell mixture that was CD32 and NKp442 cells, devoid of T H 17 and ILC3s.
Phenotypic characterization of cells before and after culture
PBMCs from healthy donors were activated in culture with IL2 and/or AhR as described above. After 14 days, the cells were stained for FACS analysis. Three-color flow cytometry was performed using the indicated mAbs: anti-human NKp44 (Phycoerythrin [PE], BioLegend, San Diego, Calif), mouse anti-human NKp44 (Allophycocyanin [APC], BioLegend), mouse anti-human NKp44 (Fluorescein isothiocyanate [FITC] , Miltenyi Biotec), mouse anti-human CD3 (FITC, BioLegend), mouse anti-human CD3 (APC, BioLegend), mouse anti-human RORgt (APC, BioLegend), mouse anti-human IL-17A (FITC, BioLegend), mouse anti-human IL-22 (PE, BioLegend), mouse anti-human TCR g/delta (APC, BioLegend), mouse anti-human CD303 (FITC, BioLegend), and mouse anti-human CD117 (PE, BioLegend). For the Lin2 gating strategy, the following antibodies were used: PE anti-CD3, TCRab, TCRgd, CD19, CD94, CD1a, CD11c, CD123, BDCA2, CD14, FcεR1, and CD34 (BioLegend). The lymphocyte population was assessed using FloJo software (Tree Star, Ashland, Ore). Some ILC3 cultured cells were further incubated for 8 more days to repeat the FACS analysis. For stimulation of cytokines production, cells were stimulated for 6 hours with the cell activation cocktail containing phorbol 12-myristate 13-acetate and ionomycin (BioLegend). Brefeldin A (BioLegend) was used for protein transport inhibition. Permeabilization and fixation of cells for the intracellular staining were performed using Leucoperm kit (Bio-Rad, Hercules, Calif). Isotype-matched control antibodies conjugated to APC, PE, and FITC were used to exclude nonspecific binding.
Sublethal irradiation on grafted mice
Normal human skin (2 normal volunteers) was grafted onto 2 SCID/Beige mice. The grafted mice underwent whole-body sublethal irradiation at a dose of 3.5 Gy/min for 2 minutes (linear accelerator, Elekta). E14 Four hours after irradiation, purified ILC3 cells were injected into the transplanted human skin. On day 30 after irradiation and cell injection, mice were sacrificed.
E15
OKT3 injections into the grafts
In another control group, we used anti-CD3 OKT3 antibodies that mediate human T-cell depletion. Mice were divided into 2 groups. IL-2-induced PBMCs or ILC3 cells were injected intradermally into the transplanted grafts of 3 mice each per group. Following cell injection, 0.04 mg of intradermal anti-CD3 antibodies (OKT3, Miltenyi Biotech) was injected daily for each of 30 days thereafter.
Immunohistochemical analysis
The following antibodies were used for frozen section: anti-IL-22 (Millipore, Burlington, Mass) and anti-TNF-a (Abcam, Cambridge, United Kingdom). For paraffin staining procedures, the following antibodies were used: antipsoriasin (S100A7), anti-IFN-g (Abcam), anti-HLA-DR (Abcam), anti-CD8 (DAKO), anti-CD4 (DAKO), anti-Ki67 (Invitrogene, Carlsbad, Calif), antiplasmacytoid (Novus Biologicals, Littleton, Colo), anti-IL-17 (R&D Systems, Minneapolis, Minn), anti-IL-22 (Millipore), and antiHuman-beta defensin (Peprotech, Rocky Hill, NJ). For HLA-DR, S100A7, and HBD2, Image analysis was performed using Image J software. Staining was calculated as the percent of staining coverage within the epidermis.
Immunofluorescence
To identify the in situ localization of ILC1 and ILC3, the following relevant markers were used in a single fluorescence channel (Lin2, using the above Lin-antibodies). Another channel was used for the identification of Tbet. RORgt and NKp44 were used in a third fluorescence channel.
Cytokine analyses in culture medium by ELISA Production of IL-17 and IL-22 by ILC3s, T H 17 cells, PBMCs, and CD32/ NKp442 groups was analyzed using ELISA. The concentrations of IL-17 and IL-22 were determined using the Human IL-17/IL-22 ELISA deluxe set (BioLegend), according to the manufacturer's protocol. mRNA extraction and real-time PCR NK-enrichment kit (Stem Cell Technologies, Vancouver, British Columbia, Canada). ILC1 cells were sorted (Aria, cell sorter) to 99% purity as Lineage-(elaborated in the section above), CD1271, CRTH2, NKp442, c-KIT2, and CD1611 cells. E16,E17 ILC2s were sorted as follows: Lineage2, CD1271, CRTH1, c-KIT2, and CD1611.
E16,E18,E19
Statistical analysis
The study parameters of each group were compared using the Kruskal-Wallis test, followed by a Mann-Whitney U test. Statistical significance was set at P < .05.
HUMANIZED MOUSE MODEL OF PSORIASIS
The humanized psoriatic severe combined immunodeficient (SCID)/beige mouse model uses healthy human skin grafts that are injected with autologous PBMCs after having been cultured in the presence of high-dose IL-2 (IL-2-activated PBMCs). This promotes the growth of different cell PBMCs, which are enriched for activated T cells bearing NK receptors. E4 It is well known that human psoriasis is successfully treated by TNF-a inhibitors, IL-23 inhibitors, or IL-17 inhibitors. These cytokines are indeed highly expressed in the induced skin lesions of the humanized mouse model. Clearance of the induced lesions was observed after treatment with either IL-23 or TNF-a inhibitors (data not shown) as well as with IL-17 inhibitor. E4 
RESULTS
Purified ILC3s retain their phenotype in vitro and in vivo
FACS analysis showed that purified ILC3s retained their cellular identity after 8 days of incubation in vitro and in vivo ( Fig E4) and did not differentiate into other cell types (Fig E4, 
E-H).
Grafts treated with IL-2-enriched PBMCs but not with OKT3 demonstrate psoriatic macroscopic and histologic features, whereas treatment with OKT3 prevented the induction of psoriasis (Fig E4, I-O) . 
